169 related articles for article (PubMed ID: 35809685)
41. Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors.
Amin MB
Mod Pathol; 2005 Feb; 18 Suppl 2():S131-45. PubMed ID: 15502808
[TBL] [Abstract][Full Text] [Related]
42. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
43. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
44. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.
Goldblum J; Hart WR
Am J Surg Pathol; 1995 Oct; 19(10):1124-37. PubMed ID: 7573671
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract][Full Text] [Related]
46. Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases.
Argani P; Lian DWQ; Agaimy A; Metzler M; Wobker SE; Matoso A; Epstein JI; Sung YS; Zhang L; Antonescu CR
Am J Surg Pathol; 2021 May; 45(5):653-661. PubMed ID: 33399341
[TBL] [Abstract][Full Text] [Related]
47. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.
Brusegard K; Stavnes HT; Nymoen DA; Flatmark K; Trope CG; Davidson B
Virchows Arch; 2012 Feb; 460(2):193-202. PubMed ID: 22249560
[TBL] [Abstract][Full Text] [Related]
48. EWSR1::YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: Report of 3 cases in support of an emerging entity.
Dermawan JK; Torrence D; Lee CH; Villafania L; Mullaney KA; DiNapoli S; Sukhadia P; Benayed R; Borsu L; Agaram NP; Nash GM; Dickson BC; Benhamida J; Antonescu CR
Genes Chromosomes Cancer; 2022 Oct; 61(10):592-602. PubMed ID: 35665561
[TBL] [Abstract][Full Text] [Related]
49. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
[TBL] [Abstract][Full Text] [Related]
50. Testicular/paratesticular mesothelial tumours: Uncommon histopathologic entities in a very complex anatomical site.
Pagliuca F; Lucà S; De Sio M; Arcaniolo D; Facchini G; De Martino M; Esposito F; DE Vita F; Chieffi P; Franco R
Pathol Res Pract; 2024 Jan; 253():155069. PubMed ID: 38181581
[TBL] [Abstract][Full Text] [Related]
51. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
52. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
53. Solid papillary mesothelial tumor.
Churg A; Le Stang N; Dacic S; Pissaloux D; Begueret H; Dartigues P; Giusiano-Courcambeck S; Sequeiros R; Pairon JC; Tirode F; Galateau-Sallé F
Mod Pathol; 2022 Jan; 35(1):69-76. PubMed ID: 34480081
[TBL] [Abstract][Full Text] [Related]
54. Immunophenotypic analysis of ovarian and testicular Müllerian papillary serous tumors.
Carano KS; Soslow RA
Mod Pathol; 1997 May; 10(5):414-20. PubMed ID: 9160304
[TBL] [Abstract][Full Text] [Related]
55. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.
Brenne K; Nymoen DA; Reich R; Davidson B
Am J Clin Pathol; 2012 Feb; 137(2):240-7. PubMed ID: 22261449
[TBL] [Abstract][Full Text] [Related]
56. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
[TBL] [Abstract][Full Text] [Related]
57. Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis.
Chekol SS; Sun CC
Arch Pathol Lab Med; 2012 Jan; 136(1):113-7. PubMed ID: 22208496
[TBL] [Abstract][Full Text] [Related]
58. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
Prat J; De Nictolis M
Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
[TBL] [Abstract][Full Text] [Related]
59. Metastatic appendiceal mucinous adenocarcinoma to well-differentiated diffuse mesothelioma of the peritoneal cavity: a mimicker of florid mesothelial hyperplasia in association with neoplasms.
Tran TA; Holloway RW; Finkler NJ
Int J Gynecol Pathol; 2008 Oct; 27(4):526-30. PubMed ID: 18753969
[TBL] [Abstract][Full Text] [Related]
60. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation.
Levy AD; Arnáiz J; Shaw JC; Sobin LH
Radiographics; 2008; 28(2):583-607; quiz 621-2. PubMed ID: 18349460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
